-
Immune Thrombocytopenia (ITP) Market Share, Size, Trends, Growth, Opportunities, And Regional Forecast To 2027
18 Oct 2021 09:18 GMT
… , Chi-Med Initiated a Phase I Trial of HMPL … many conditions. Moreover, Pharmaceutical companies, physicians, and … advanced drugs. Scientists globally are working urgently to develop treatments. … . Therefore to develop effective, safe medications and doses, …
-
Immune Thrombocytopenia Pipeline Drugs and Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
14 Oct 2021 21:51 GMT
… drugs in Immune Thrombocytopenia (ITP) pipeline landscape. It covers the pipeline drug profiles … , Amgen, Dova Pharmaceuticals, Novartis, etc., are developing therapies for the treatment of the …
-
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share, Industry Growth, Trend, Drivers, Challenges, Key Companies by 2026
09 Sep 2021 15:04 GMT
… pharmaceutical companies on development of novel mechanisms based Idiopathic thrombocytopenic purpura drugs … Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Segmentation based … ; 2016–2026) Drug store Retail pharmacies Others Treatment Type of …
-
Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China – Press Release
01 Sep 2021 06:39 GMT
… New Drug (IND) application to initiate phase II trial of … developing batoclimab (HBM9161) as a pipeline in a product to treat … ophthalmopathy, adult immune thrombocytopenia (ITP) and neuromyelitis optica … and leads to the treatment of pathogenic IgG-mediated …
-
FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis
30 Aug 2021 13:19 GMT
… treatment of adult dermatomyositis (DM).
“The FDA approval of orphan drug … status for Octagam® 10% to treat … from the ProDERM clinical trial.”
Dermatomyositis is a … manufacturers in the world, developing and producing human proteins …
-
FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%
31 Aug 2021 05:47 GMT
… and Drug Administration (FDA) Office of Orphan Products Development ( … treatment of adult dermatomyositis (DM).
The FDA approval of orphan drug … status for Octagam® 10% to treat … from the ProDERM clinical trial."
Flemming Nielsen …
-
InnoCare Pharma gets China NMPA nod to begin phase II trial of orelabrutinib to treat primary immune thrombocytopenia
12 Aug 2021 14:33 GMT
InnoCare Pharma, a biopharmaceutical company, announced the Investigational New Drug (IND) approval … phase II clinical trial in primary immune thrombocytopenia (ITP) in China.
… selective BTK inhibitor developed by InnoCare for the treatment of cancers and …
-
Royalty Pharma Reports Second Quarter 2021 Results
11 Aug 2021 12:06 GMT
… Portfolio
The key developments related to Royalty Pharma';s royalty … 312, a Phase 3 trial evaluating Cabometyx in combination … of Tysabri to treat relapsing-remitting multiple sclerosis. … approved by the FDA and EMA for the treatment of primary hyperoxaluria …
-
GlaxoSmithKline files for FDA Approval of Platelet-boosting Treatment
27 Jun 2021 21:35 GMT
… based pharmaceutical and healthcare companies has filed for FDA approval … with chronic ITP do not have a treatment option that … of the Oncology Medicine Development Center at GSK.
“ … ITP patients with a new, convenient and effective option for treating …
-
Intervention program for developmental delays ready for influx of children missed during pandemic
23 Jun 2021 01:07 GMT
… ;s Infant-Toddler Program (NC ITP). "Research has also shown … only affects brain development, but really can help remedy any delays.… spread across the state, NC ITP switched to an all-virtual …
About
© 1995-2021